Literature DB >> 6481180

Cutaneous basophil hypersensitivity to inhalant allergens in atopic dermatitis patients: elicitation of delayed responses containing basophils following local transfer of immune serum but not IgE antibody.

E B Mitchell, J Crow, S Rowntree, A D Webster, T A Platts-Mills.   

Abstract

Inhalant allergens applied to the skin of sensitive atopic dermatitis patients by means of a modified patch test technique, induce acute eczematous lesions. These lesions contain basophils, eosinophils, mononuclear cells, and neutrophils and represent an example of human cutaneous basophil hypersensitivity. The role of IgE antibody in this eczematous reaction was studied by systemic and local passive transfer experiments. Plasma with high IgE antibody when infused into patients with hypogammaglobulinemia as part of their replacement treatment resulted, post infusion, in cutaneous mast cell and blood basophil sensitization as measured by quantitative skin testing and leukocyte histamine release. Subsequent patch tests on these patients using the house dust mite antigen, antigen P1, produced macroscopic erythematous responses containing mononuclear cells, and eosinophils but not basophils. Local transfer of atopic dermatitis serum with high IgE antibody produced weak macroscopic responses and in these lesions mononuclear cells and both basophils and eosinophils were present. The serum activity which allowed transfer of basophil and eosinophil recruitment was heat labile. Specifically purified antibody to the mite antigen P1 (containing IgE and IgG antibody), when transferred, allowed eosinophil but not basophil recruitment to patch test sites. These results suggest that while the allergen-induced patch test response may involve IgE antibodies, as well as the cells normally involved in delayed responses, another serum activity is also involved.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6481180     DOI: 10.1111/1523-1747.ep12340423

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

Review 1.  New approaches to environmental control.

Authors:  J W Vaughan; T A Platts-Mills
Journal:  Clin Rev Allergy Immunol       Date:  2000-06       Impact factor: 8.667

Review 2.  Aeroallergen contact dermatitis.

Authors:  A Taïeb; G Ducombs
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

Review 3.  Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease.

Authors:  Monica G Lawrence; Judith A Woodfolk; Alexander J Schuyler; Leland C Stillman; Martin D Chapman; Thomas A E Platts-Mills
Journal:  J Allergy Clin Immunol       Date:  2016-07-14       Impact factor: 10.793

4.  IgE antibodies to D. pteronyssinus in atopic patients.

Authors:  S J Thompson; H J Whitley; J D Naysmith; F Carswell
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

Review 5.  Dust mite allergens and asthma: a worldwide problem. International Workshop report.

Authors: 
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

6.  Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice.

Authors:  J M Spergel; E Mizoguchi; J P Brewer; T R Martin; A K Bhan; R S Geha
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

7.  Production and secretion of interferon-gamma (IFN-gamma) in children with atopic dermatitis.

Authors:  M Tang; A Kemp
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

8.  In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart.

Authors:  Francis Man; Alexander Koers; Panagiotis Karagiannis; Debra H Josephs; Heather J Bax; Amy E Gilbert; Tihomir S Dodev; Silvia Mele; Giulia Chiarruttini; Silvia Crescioli; Jitesh Chauhan; Julia E Blower; Margaret S Cooper; James Spicer; Sophia N Karagiannis; Philip J Blower
Journal:  Oncoimmunology       Date:  2021-09-06       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.